Trans-scleral iontophoretic delivery of low molecular weight therapeutics

S Güngör, M Begona Delgado-Charro, B Ruiz-Perez, W Schubert, P Isom, P Moslem, M A Patane, Richard H Guy

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)
197 Downloads (Pure)

Abstract

The fundamental understanding of ocular drug delivery using iontophoresis is not at the same level as that for transdermal electrotransport. Research has therefore been undertaken to characterise the electrical properties of the sclera (charge, permselectivity, and isoelectric point (pI)) and to determine the basics of iontophoretic transport of model neutral, cationic, and anionic species (respectively, mannitol, timolol, and dexamethasone phosphate). Like the skin, the sclera supports a net negative charge under physiological pH conditions and has a pI between 3.5 and 4. Equally, the principles of trans-scleral iontophoretic transport of low molecular weight compounds are consistent with those observed for skin. Iontophoretic delivery of timolol and dexamethasone phosphate was proportional to applied current and drug concentration, and trans-scleral iontophoresis in rabbits led to enhanced intraocular levels of these compounds compared to passive delivery. The behaviour of higher molecular weight species such as peptide drugs and other biopharmaceuticals (e.g., proteins and oligonucleotides) has not been fully characterised. Further work has been undertaken, therefore, to examine the trans-scleral iontophoresis of vancomycin, a glycopeptide antibiotic with a relatively high molecular weight of 1448 Da. It was indeed possible to deliver vancomycin by iontophoresis but trans-scleral transport did not increase linearly with either increasing current density or peptide concentration.
Original languageEnglish
Pages (from-to)225-231
Number of pages7
JournalJournal of Controlled Release
Volume147
Issue number2
DOIs
Publication statusPublished - Oct 2010

Fingerprint Dive into the research topics of 'Trans-scleral iontophoretic delivery of low molecular weight therapeutics'. Together they form a unique fingerprint.

Cite this